WallStSmart

Bioatla Inc (BCAB)vsRevolution Medicines Inc (RVMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Bioatla Inc generates 170% more annual revenue ($2.00M vs $742,000). RVMD leads profitability with a 0.0% profit margin vs 0.0%. BCAB earns a higher WallStSmart Score of 34/100 (F).

BCAB

Avoid

34

out of 100

Grade: F

Growth: 6.3Profit: 2.5Value: 5.0Quality: 4.5
Piotroski: 2/9Altman Z: -70.46

RVMD

Avoid

24

out of 100

Grade: F

Growth: 3.7Profit: 3.0Value: 5.0Quality: 6.0
Piotroski: 1/9Altman Z: -0.99

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BCAB2 strengths · Avg: 10.0/10
Revenue GrowthGrowth
31.6%10/10

Revenue surging 31.6% year-over-year

Debt/EquityHealth
-0.1610/10

Conservative balance sheet, low leverage

RVMD1 strengths · Avg: 9.0/10
Debt/EquityHealth
0.109/10

Conservative balance sheet, low leverage

Areas to Watch

BCAB4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$5.85M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

RVMD4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : BCAB

The strongest argument for BCAB centers on Revenue Growth, Debt/Equity. Revenue growth of 31.6% demonstrates continued momentum.

Bull Case : RVMD

The strongest argument for RVMD centers on Debt/Equity.

Bear Case : BCAB

The primary concerns for BCAB are EPS Growth, Market Cap, Profit Margin.

Bear Case : RVMD

The primary concerns for RVMD are EPS Growth, Profit Margin, Operating Margin.

Key Dynamics to Monitor

BCAB profiles as a hypergrowth stock while RVMD is a value play — different risk/reward profiles.

RVMD carries more volatility with a beta of 1.41 — expect wider price swings.

BCAB is growing revenue faster at 31.6% — sustainability is the question.

BCAB generates stronger free cash flow (-5M), providing more financial flexibility.

Bottom Line

BCAB scores higher overall (34/100 vs 24/100) and 31.6% revenue growth. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Bioatla Inc

HEALTHCARE · BIOTECHNOLOGY · USA

BioAtla, Inc., a biopharmaceutical company, develops specific and selective antibody-based therapies for the treatment of various cancers. The company is headquartered in San Diego, California.

Revolution Medicines Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.

Want to dig deeper into these stocks?